中国药物警戒 ›› 2026, Vol. 23 ›› Issue (2): 207-209.
DOI: 10.19803/j.1672-8629.20250469

• 安全与合理用药 • 上一篇    下一篇

替吉奥胶囊致胃癌患者重症间质性肺炎1例分析

孟德辉1, 王超2, 李华1, 丁春雷1,*   

  1. 1北京美中爱瑞肿瘤医院药剂科，北京 100176;
    2北京美中爱瑞肿瘤医院乳腺癌肿瘤中心，北京 100176
  • 收稿日期:2025-07-16 出版日期:2026-02-15 发布日期:2026-02-13
  • 通讯作者: *丁春雷，男，硕士，主管药师，药事管理。E-mail: chunlei.ding@arion.care
  • 作者简介:孟德辉，女，硕士，主管药师，抗肿瘤药物研究。

One Case of Severe Interstitial Lung Disease Caused by Tegafur Gimeracil Oteracil Potassium Capsules for the Treatment of Gastric Cancer

MENG Dehui1, WANG Chao2, LI Hua1, DING Chunlei1,*   

  1. 1Department of Pharmacy, Beijing Arion Cancer Center, Beijing 100176, China;
    2Breast Cancer Center, Beijing Arion Cancer Center, Beijing 100176, China
  • Received:2025-07-16 Online:2026-02-15 Published:2026-02-13

PDF (PC)

1

摘要： 目的 探讨口服替吉奥胶囊导致胃癌患者重症间质性肺炎的不良反应，为临床安全用药提供参考。方法 对1例口服替吉奥治疗胃癌过程中出现重症间质性肺炎的临床资料进行分析，并对国内外相关文献进行回顾总结。结果 本例患者重启替吉奥治疗3 d出现发热伴恶心呕吐，胸部CT示双肺间质性肺炎症状较1周前加重，经多学科会诊讨论及关联性分析判断间质性肺炎为替吉奥所致，停用替吉奥，给予甲泼尼龙及呼吸机辅助通气治疗，患者逐渐改善。结论 替吉奥致间质性肺炎虽罕见，但可能导致严重的呼吸衰竭而危及生命。临床使用替吉奥应注意药品不良反应，做好用药评估。若患者出现发热、呼吸困难等症状，应及时完善相关检查，根据间质性肺炎分级采取相应的处理措施，改善患者预后。

关键词: 替吉奥, 甲泼尼龙, 间质性肺炎, 胃癌, 药品不良反应

Abstract: Objective To analyze such adverse reactions as severe interstitial lung disease (ILD) caused by S-1 (tegafur gimeracil oteracil potassium) capsules in a patient with gastric cancer, and to provide a reference for clinicians. Methods The clinical data of a patient who developed ILD during the treatment of her gastric cancer with oral S-1 was analyzed. The related literature was reviewed and summarized. Results The patient developed fever accompanied by nausea and vomiting three days into the re-treatment with S-1. Chest CT showed that ILD symptoms worsened compared with the previous week. After multidisciplinary consultation and correlation analysis, the patient was diagnosed with S-1-induced ILD. S-1 was discontinued before methylprednisolone and ventilator-assisted ventilation were used. The patient’s clinical symptoms and chest CT findings gradually improved. Conclusion Although S-1-induced ILD is rare, it may lead to severe respiratory failure and is even life-threatening. Clinicians should be alert to the risk of adverse drug reactions and conduct a safety assessment before prescribing S-1. Related examinations should be completed soon after patients develop such symptoms as fever or dyspnea. If S-1-induced ILD is considered likely, clinicians should adopt the right treatment regimen according to the ILD grade to improve the patient’s prognosis.

Key words: Tegafur Gimeracil Oteracil Potassium, Methylprednisolone, Interstitial Lung Disease, Gastric Cancer, Adverse Drug Reactions

中图分类号: